In contrast, past strategies to develop vaccines for synucleinopathies have utilized linear peptides or linear epitopes that merely mimic alpha‐synuclein in its native form,33, 34, 35, 36, 37, 38, 39 lacking control over the structure of the antigen used for immunization and failing to imitate pathological alpha‐synuclein in its aggregated/amyloid form. The gene discussed is SNCA; the disease is synucleinopathy.